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Abstract
Background and objective: T-cell immunoglobulin domain and mucin domain-containing molecule-3 (Tim-3)
represents a novel mechanism of T-cell dysfunction in chronic viral diseases. However, the role of Tim-3 in the
pathogenesis of chronic hepatitis B (CHB) is not well understood. We investigated Tim-3 expression on peripheral T
cell subsets and analyzed the relationship between Tim-3 expression and disease progression in HBV infection.
Methods: peripheral blood samples were obtained from CHB patients (n = 40), including 23 patients with
moderate CHB [MCHB] and 17 with severe CHB [SCHB]. Control samples were obtained from nine acute hepatitis B
patients (AHB) and 26 age-matched healthy subjects. The expression of Tim-3 on T cells was determined by flow
cytometry.
Results: Tim-3 expression was elevated on peripheral CD4
+ and CD8
+ T cells from AHB and CHB patients
compared to those from healthy controls. The percentage of Tim-3
+ T cells was further increased in SCHB patients
relative to MCHB patients and showed a positive correlation with conventional markers for liver injury (alanine
aminotransferase (ALT), aspartate transaminase (AST), total bilirubin (TB) and international normalized ratio (INR)
level). The frequency of Tim-3-expressing T cells was negatively correlated with T-bet mRNA expression and plasma
interferon-gamma (INF-gamma) levels. Further, Tim-3 expression on CD4
+ or CD8
+ T cells was reduced in CHB
patients with disease remission after antiviral treatment and in AHB patients during the convalescence phase.
Conclusions: Our results suggest that over-expression of Tim-3 is involved in disease progression of CHB and that
Tim-3 may participate in skewing of Th1/Tc1 response, which contributes to persistency of HBV infection.
Introduction
Chronic hepatitis B virus (HBV) infection is a global health
burden with 350-400 million people infected worldwide.
Approximately 1 million deaths occur annually due to the
long-term complications of infection including cirrhosis,
liver failure and hepatocellular carcinoma [1]. Adaptive T-
cell immunity plays a pivotal role in viral clearance [2].
Patients chronically infected with HBV present impaired T
helper 1 cells (Th1) response and consequently impaired
cytotoxic T lymphocyte (Tc1) priming, which results in
viral persistence and liver damage [3]. In contrast those
who recovered from acute HBV infection (AHB) exhibit
normal Th1 and Tc1 function. The cause(s) of T-cell dys-
function in chronically infected patients have not been
fully clarified.
Recent studies have focused on the role of membrane
inhibitory receptors in modulating T-cell dysfunction
during chronic viral diseases. Programmed cell death-1
(PD-1), a member of the CD28 family, was found to be
up-regulated on the surfaces of exhausted T cells during
chronic lymphocytic choriomeningitis virus (LCMV) [4],
human immunodeficiency virus (HIV) [5], hepatitis C
virus (HCV) [6] and HBV infections [7]. Furthermore,
blockade of this pathway ex vivo or in vivo significantly
improved T-cell function. However, T-cell exhaustion
was not always completely corrected by blocking the
PD-1 pathway, suggesting that other pathways may
involved in T-cell dysfunction [8].
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containing molecule-3 (Tim-3) was first found to be
expressed on Th1 but not Th2 cells [9]. Tim-3 nega-
tively regulates Th1 response and induces tolerance
through the Tim-3/Galectin-9 pathway in autoimmune
diseases [10]. Tim-3 is highly expressed on effector T
cells during HIV and HCV infection, and blocking the
Tim-3 signaling pathway restores proliferation and
enhanced cytokine production of effector T cells [11,12].
Furthermore, a synergistic effect was observed by block-
ing both the Tim-3 and PD-1 pathway during chronic
LCMV infection [13]. Taken together, these results indi-
cated that Tim-3 might be another negative regulatory
receptor contributing to T-cell dysfunction.
However, the role of Tim-3 in HBV infection has not
been clarified. Therefore we investigated the expression
of Tim-3 on peripheral T cells in patients chronically
infected with hepatitis B and tested whether the expres-
sion level of Tim-3 correlates with disease progression.
Materials and methods
Subjects
S a m p l e sw e r eo b t a i n e df r o mH B V - i n f e c t e dp a t i e n t s
admitted to the infectious department of our hospital,
including with 23 with mild CHB (MCHB), 17 with
severe CHB (SCHB), 9 with AHB and 26 healthy con-
trols. The demographic features of study group are pre-
sented in Table 1. The mean age of SCHB patients was
higher than that of the other three groups. There was
no significant difference in sex proportion among the
groups.
T h ec r i t e r i af o rd i a g n o s i so fA H Ba n dC H Bw e r e
described in detail previously [14]. SCHB was diagnosed
if serum total bilirubin (TBIL) [15] exceed 10 times of
normal upper limit (171 uM) and prothrombin time
activity (PTA) exceed 40%, while those with TBIL less
than 171 uM and PTA less than 40% were diagnosed as
MCHB. We excluded individuals co-infected with hepa-
titis C virus (HCV), hepatitis D virus (HDV) and human
immunodeficiency virus (HIV); persons with other
causes of chronic liver diseases such as autoimmune
hepatitis and Wilson disease; patients with suspected
signs of hepatocellular carcinoma (HCC) by ultrasound
or serum AFP; and anyone who received antiviral treat-
ment within the previous 6 months. This study was
approved by the local ethics committee and we obtained
written informed consent from each study participant.
The study was carried out in accordance with Declara-
tion of Helsinki.
Virological assessment
Serological markers of HBV, HCV, HDV and HIV were
tested by commercial enzyme immunoassay kits
(AXSYM System, Abbott, Wiesbaden, Germany) as pre-
viously described [16]. Serum HBV DNA level was
determined using a quantitative polymerase chain reac-
tion (qPCR) assay (PG Biotech, Shenzhen, China). The
lower detection limit threshold is 500 copies/ml.
PBMC isolation
Peripheral blood mononuclear cells (PBMCs) were isolated
from fresh-heparinized blood by standard Ficoll-Hypaque
density centrifugation (Biochrom, Berline, Germany).
PBMC isolation was performed no more than 2 hours after
peripheral blood was collected by venipuncture.
Flow cytometric analysis
For Tim-3 expression analysis, freshly-isolated PBMCs
were stained with anti-CD3-APC, anti-CD4-FITC or
anti-CD8-FITC (BD Biosciences) and anti-TIM-3-PE
Table 1 Clinical characteristics of the studied groups
Variables N.C. (N = 26) AHB (N = 9) MCHB (N = 23) SCHB (N = 17)
Age (year) 30.2 ± 5.4 32.7 ± 13.5 33.1 ± 11.4 42.8 ± 13.1
Sex 69.2 88.9 70.0 70.6
HBsAg (%) 0 77.8 100 100
HBsAb (%) 61.5 22.2 0 0
HBeAg (%) 0 77.8 50 35.7
HBeAb (%) 3.8 22.2 50 71.4
HBcAb (%) 34.6 100 100 100
Log HBV DNA NA 4.66 ± 2.95 6.87 ± 1.59 4.34 ± 3.07
ALT (IU/L) 15.3 ± 9.2 1197.5 ± 804.7 360.6 ± 344.6 487.8 ± 775.9
AST (IU/L) 11.7 ± 6.8 537.1 ± 539.0 241.7 ± 261.3 417.2 ± 597.1
Bilirubin (umol/L) 14 ± 11.1 113.2 ± 105.6 65.6 ± 55.2 332.5 ± 179.6
INR NA 1.14 ± 0.26 1.02 ± 0.12 2.32 ± 0.85
Data were expressed as mean ± SD or percentage; N.C.: normal control; AHB: acute hepatitis B; MCHB: moderate chronic hepatitis B; SCHB: severe chronic
hepatitis B; ALT: alanine aminotransferase; AST: aspartate transaminase; INR: international normalized ratio.
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matched antibodies (Beckman Coulter) were used as
controls. At least 1×10
5 cells were analyzed using a
Beckman Coulter flow cytometer (FC500 MPL, Fuller-
ton, CA, USA).
Quantification of T-bet mRNA by real-time PCR
Total RNA was extracted from freshly isolated PBMCs
according to the manufacturer’s protocol (Invitrogen,
Carlsbad, CA). The T-bet mRNA was determined by per-
forming a real-time PCR with SYBR-green I Premix
ExTaq on the ABI Prism 7900 (Applied Bio systems, Fos-
ter, CA). The primer pairs were used as follow: T-bet-for-
ward: TGTGACCCAGATGATTGTGC; T-bet-reverse:
AAAGATATGCGTGTTGGAAGC; GAPDH-forward:
GGTGGTCTCCTCTGACTTCAACA; GAPDH-reverse:
GTTGCTGTAGCCAAATTCGTTGT. All PCR assays
were performed in duplicate, and data were analyzed
with the ABI Prism Detection system using the compara-
tive threshold cycle method as previously described.
GAPDH was used as internal control and RNA samples
from the healthy groups were used as quality control in
each RT-PCR.
Quantification of plasma INF-gamma by flow-cytomix
Plasma INF-gamma level was determined using the
flow-cytomix simplex kit, according to the manufac-
turer’s instructions (Bender MedSystem, Copenhagen,
Denmark). The detection thresholds were 1.6 pg/ml.
Statistical analysis
Data were expressed as mean ± SD or number (%). The
Mann-Whitney U test and Chi-Square test were used to
compare differences among the study groups. The
paired t test was used to compare differences in Tim-3
expression before and after treatment, at early phase,
and at convalescence stage. Spearman correlation was
conducted to assess the association between the fre-
quency of Tim-3-expressing T cells and the other indi-
cated parameters. A P value of less than 0.05 was
Figure 1 Elevated Tim-3 expression on circulating CD4 and CD8 T cells in HBV-infected individuals. (A) PBMCs from normal controls, AHB
patients (early phase), MCHB and SCHB patients were stained with antibodies against CD3, CD4/CD8, and Tim-3. An isotype-matched antibody
was used as a negative control. (B) The percentage of Tim-3 cells within CD4+ and CD8+ T cell populations are increased in AHB and CHB
patients and further enhanced in the severe stage of CHB. Each dot represents an individual data point and the horizontal lines represent the
mean. The Mann-Whitney U test was used to compare differences among groups. (C) There is a significantly positive correlation between the
frequency of Tim-3-expressing CD4
+ and CD8
+ T cells in the studied subjects. Spearman test was performed for correlation analysis.
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analysis was performed with SPSS 16.0 for Windows
(SPSS, Chicago, IL).
2 Results
2.1 Up-regulation of Tim-3 expression on peripheral T-cell
subsets in HBV-infected subjects
We examined Tim-3 expression from patients in the
three groups by flow cytometry on PBMCs using an
anti-Tim-3 polyclonal antibody. An elevated frequency
of Tim-3-positive CD4
+ cells was observed in subjects
with AHB (onset) and CHB compared to non-infected
controls (1.48 ± 0.83% for normal controls versus 3.58 ±
1.90% for patients with AHB [P < 0.0001], 3.93 ± 2.76%
for CHB patients [P < 0.0001], Figure 1A and 1B). We
also observed increased Tim-3 expression on CD8
+ T
cells from AHB and CHB patients, relative to normal
controls (6.43 ± 2.50% for controls versus 27.12 ± 6.33%
for AHB patients [P < 0.0001] and 21.34 ± 11.95% for
CHB patients, Figure 1A and 1B). Patients with AHB
presented higher Tim-3 expression on CD8
+ (P = 0.040)
but not CD4
+ T cells (P = 0.796) relative to CHB
patients. Tim-3 expression on both CD4
+ (P < 0.0001)
and CD8
+ (P < 0.0001) T cells was significantly elevated
in SCHB patients compared to that in MCHB patients.
Furthermore, the frequency of Tim-3-expressing CD4
+
Figure 2 Association between the frequency of Tim-3
+ T cells and conventional markers for liver damage in CHB patients.T h e
frequency of CD4
+ or CD8
+ T cells expressing Tim-3 are positively correlated with the levels of laboratory parameters for assessing liver injury
such as ALT (A), AST (B), TB (C) and INR (D). Spearman test was used for correlation analysis.
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CD8
+ T cells (r = 0.792, P < 0.0001, Figure 1C). Taken
together these results indicate that Tim-3 expression is
increased in parallel with disease severity.
2.2 The frequency of Tim-3-expressing T cells correlates
with hepatic injury but not viral load in CHB patients
We then evaluated the correlation between Tim-3 expres-
sion and established markers for liver damage. We found
that the frequency of Tim-3
+ CD4
+ or CD8
+ T cells signif-
icantly correlated with levels of alanine aminotransferase
(ALT) (rCD4 =0 . 3 7 1 ,P CD4 = 0.020; rCD8 = 0.371, PCD8 =
0.001), aspartate transaminase (AST) (rCD4 = 0.496,
PCD4 =0 . 0 0 1 ;r CD8 =0 . 6 1 8 ,P CD8 < 0.0001), international
normalized ratio (INR) (rCD4 =0 . 4 9 8 ,P CD4 = 0.001; rCD8 =
0.490, PCD8 = 0.002), and total bilirubin (rCD4 = 0.610,
PCD4 < 0.0001; rCD8 =0 . 6 4 9 ,P CD8 < 0.0001) (Figure 2).
These results suggest that Tim-3 could be used as a poten-
tial marker for assessing severity of hepatic injury in CHB.
As it was reported that Tim-3 expression was associated
viral load during HIV infection, we examined whether this
relationship was established in chronic HBV infection.
However, we did not observe a significant correlation
between serum HBV DNA with the frequency of either
Tim-3+ CD4
+ T cells (rCD4 = -0.211, PCD4 = 0.204) or
Tim-3+ CD8
+ T cells (rCD4 = -0.206, PCD4 = 0.215).
2.3 The frequency of Tim-3-positive T cells negatively
correlates with T-bet mRNA expression in CHB patients
Tim-3 was reported to negatively regulate the Th1/Tc1
response. As T-bet was a Th1/Tc1-related transcription
factor, we determined T-bet mRNA expression in PBMCs
from healthy controls, AHB patients and CHB patients.
The relative amount of T-bet mRNA expression in
patients was 0.89 fold of healthy controls (P = 0.020).
However, there was no significant difference between
CHB (0.89 fold of healthy controls) and AHB patients
(0.86 fold of healthy controls) (P = 0.178). Lower T-bet
mRNA expression was observed in SCHB patients (0.53
fold of healthy controls) compared to MCHB patients
Figure 3 Association between the frequency of Tim-3
+ T cells and T-bet mRNA expression in CHB patients. (A) T-bet mRNA expression was
determined in patients separated into four groups: normal controls (N = 12), AHB patients (early phase) (N = 7), MCHB patients (N = 15) and SCHB
patients (N = 10). The bars represent the (95% CI) T-bet mRNA expression for each group and the differences among groups were analyzed using the
Mann-Whitney U test. (B) Spearman correlation analysis showed a negative association between the frequency of Tim-3-postivie T cells and T-bet
mRNA expression.
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Moreover, we observed a significant inverse correlation
between T-bet mRNA expression and the frequency of
Tim-3
+ T cells (rCD4 = -472, PCD4 = 0.023; rCD8 = -0.591,
PCD8 = 0.003) (see Figure 3B). However, these correlations
were not observed in AHB patients (data not shown).
2.4 The frequency of Tim-3-positive T cells negatively
correlates with plasma IFN-gamma level in CHB patients
We next assessed plasma levels of IFN-gamma, a Th1/Tc1-
related cytokine, in 12 uninfected controls, 7 AHB patients
and 25 CHB patients. Plasma IFN-gamma concentration
were significantly lower in CHB patients relative to AHB
patients and controls (INF-gamma: 28.16 ± 34.51 pg/ml for
CHB patients versus 78.63 ± 79.92 pg/ml for AHB patients
[P = 0.045], 40.82 ± 21.58 for normal controls [P = 0.032])
(see Figure 4A). Moreover, we observed a significant inverse
correlation between plasma IFN-gamma and the frequency
of Tim-3
+ Tc e l l s( r CD4 = -0.553, PCD4 =0 . 0 0 4 ;r CD8 =
-0.450, PCD8 = 0.024) (see Figure 4B) Again, these correla-
tions were not observed in AHB patients (data not shown).
2.5 Tim-3 expression was reduced in CHB patients with
disease remission
The previous results indicated a role of Tim-3 in disease
progression of CHB. To further evaluate this hypothesis,
we conducted a longitudinal study on Tim-3 expression
on T cells from 8 CHB patients before and after anti-
viral treatment with a 3-6 month follow-up time. All the
8 patients achieved complete biochemical (ALT normal-
ization) and virological response (suppression of serum
HBV DNA to undetectable levels) after 6-months of
antiviral treatment. As shown in Figure 5A, Tim-3
expression on both CD4
+ and CD8
+ Tc e l l sw a ss i g n i f i -
cantly reduced in these patients (CD4: 2.96 ± 1.85% for
early phase versus 1.11 ± 0.36% for convalescence phase,
P = 0.028; CD8: (17.20 ± 5.89% for early phase versus
5.90 ± 2.54% for convalescence phase, P = 0.001)).
2.6 Tim-3 expression was reduced in AHB patients at
convalescence stage
We also performed follow-up of 6 AHB patients to ana-
lyze the dynamic alteration of Tim-3 expression with
Figure 4 Association between the frequency of Tim-3
+ T cells and plasma IFN-gamma level in CHB patients. (A) IFN-gamma was
measured in plasma from normal controls (N = 12), AHB patients (early phase) (N = 7), MCHB patients (N = 15) and SCHB patients (N = 10). The
bars represent the (95% CI) IFN-gamma level for each group and the differences among groups were analyzed using the Mann-Whitney U test.
(B) Spearman correlation analysis showed there were negative associations between the frequency of Tim-3-postivie T cells and plasma IFN-
gamma level.
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as ALT normalization and HBsAg-seroconversion. As
s h o w ni nF i g u r e5 B ,t h eT i m - 3
+ CD8
+ T cell frequency
of the AHB patients was high in the early acute phase
and significantly reduced in the convalescent phase
(25.27 ± 1.85% for early phase versus 3.98 ± 1.62% for
convalescence phase, P < 0.0001). Tim-3 expression on
CD4
+ T cells also appeared to be reduced although this
effect did not quite achieve statistical significance (3.97
± 2.14% for early phase versus 1.93 ± 1.18% for conva-
lescence phase, P = 0.081).
Discussion
Tim-3, expressed in both innate and adaptive immune
cells, plays a pivotal role in immune regulation and
immune tolerance [17]. A recent study showed that
HBV infection can up-regulate Tim-3 expression in NK
cells, which may in turn suppress NK-cell functions in
CHB patients [18]. Viral clearance and liver damage is
thought to be mediated primarily through T cell-
mediated responses [19], however; up to now, no study
investigated the role of Tim-3 in regulating T-cell
immunity in CHB patients. In this study, we determined
the expression profile of Tim-3 on peripheral T cell sub-
s e t sf r o mC H Ba n dA H Bp a t i e n t sa n di n v e s t i g a t e dt h e
potential role of Tim-3 in disease progression.
We first demonstrated increased Tim-3 expression on
CD4
+ and CD8
+ T cells in patients with CHB and found
that Tim-3 expression was further enhanced in samples
from patients with more severe stages of CHB. More-
over, there was a significant positive correlation between
Tim-3 expression with conventional markers for hepatic
injury such as ALT, AST, INR and TB. These results
indicate that Tim-3 expression level is related to the
degree of liver inflammation. This was further supported
by an observed decrease of Tim-3 expression in CHB
patients with disease resolution. Since activated T cells
cause liver injury, and the severity of liver inflammation
Figure 5 longitudinal analysis of Tim-3 expression in CHB and AHB patients. (A) The percentage of Tim-3
+ T cells decreased in CHB patients
after successful antiviral treatment. The frequency of Tim-3
+ cells in CD4
+ and CD8
+ T cells before and after treatment is shown. (B) The frequency
of Tim-3
+ T cells decreased in AHB patients during disease convalescence. The frequency of Tim-3
+ cells in CD4
+ and CD8
+ T cells at early stage
and convalescence stage is shown.
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T cells [19], up-regulation of Tim-3 expression might be
due to the activation of T cells.
Accumulating evidence indicates that Tim-3 could
negatively regulate adaptive immune response. Upon
interaction with its ligand, Galectin-9, Tim-3 induces
Th1 cell death and suppresses IFN-gamma production
[10]. Further, IFN-g secretion from CD4
+ and CD8
+ T
cells could be restored by blockade of the Tim-3/Galec-
tin-9 pathway or by Tim-3 knockdown using specific
shRNAs [11]. In this study, we demonstrated lower
expression of T-bet mRNA and lower levels of plasma
IFN-gamma in CHB patients compared with AHB
patients or uninfected controls, suggesting an impaired
Th1/Tc1 response in CHB patients. We further found
an inverse correlation between Tim-3 expression and
both T-bet expression and plasma IFN-gamma, in CHB
patients but not AHB patients. These results provided
suggestive evidence that Tim-3 down-regulates the Th1/
Tc1 response, which might contribute to viral persis-
tence during chronic HBV infection.
Previous work showed that Tim-3 was highly
expressed on CD4
+ and CD8
+ T cells in acutely/early
HIV infected individuals
11. Similarly, we also observed
high expression of Tim-3 on T cells during the early
stage of acute HBV infection. However, in AHB patients,
Tim-3 was expressed as a transient up-regulation, which
subsequently decreased at convalescence stage. This
Tim-3 expression pattern was in line with that of PD-1
observed during acute-limited HBV infection [20]. Tim-
3 expression was not associated with severity of hepatic
injury in AHB patients. Furthermore, unlike CHB, there
was no association between Tim-3 expression and IFN-
gamma or TNF-alpha level in AHB patients. Overall,
these results suggested a different role of Tim-3 in the
pathogenesis of AHB and CHB, which might determine
the diversification of HBV infection.
Conclusions
Collectively, the expression of Tim-3 is up-regulated on
circulating CD4
+ and CD8
+ T cells in CHB patients.
Tim-3 was highly expressed on T cells from AHB
patients as well, however, its expression decreased dyna-
mically in convalescence phase. Tim-3 expression posi-
tively correlated with disease severity and negatively
correlated with Th1/Tc1 response in CHB patients. Our
data suggest that Tim-3 might be a potential marker for
evaluating severity of hepatic flare-up. However, further
studies were needed to clarify the exact role of Tim-3 in
the pathogenesis of CHB.
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